Calumet Inc. (CLMT) Income Statement

The 40.8% revenue growth in 2026Q2 is the strongest in the ten-quarter window, yet it coincides with a gross margin of just 1.3%, suggesting that the top-line expansion may be tied to pass-through of higher feedstock costs or credit-related revenue recognition. Prior quarters show erratic revenue swings, with 2025Q3 revenue of $1.1B and 2024Q3 also at $1.1B, indicating no clear organic growth trend. Investors should monitor whether this revenue spike translates into sustainable cash generation or merely reflects timing of RIN and LCFS credit sales.

The gross margin profile is highly unstable, with negative margins in four of the last five quarters, including -8.5% in 2026Q1. This pattern suggests that the company's cost structure is heavily exposed to commodity spreads and environmental credit values, which can overwhelm the specialty products' stable margins. The 2025Q3 outlier of 34.7% gross margin appears to be an anomaly, possibly due to favorable inventory valuation or one-time gains, and should not be extrapolated as a new norm. Without a sustained improvement in feedstock spreads or credit prices, the structural low margin of 5.94% (average over the period) may persist.

SG&A expenses have remained relatively stable, ranging from $24.4M to $78.3M, but operating income has been extremely volatile, driven almost entirely by gross profit swings. In 2026Q1, SG&A spiked to $78.3M while gross profit was -$87.5M, resulting in an operating loss of $171.3M, suggesting that fixed costs are not being absorbed by revenue. This lack of operating leverage implies that the company cannot control costs enough to offset input price volatility, and any revenue growth does not translate into operating income stability. The absence of R&D expenses (reported as $0) indicates that all spending is directed to operations, yet efficiency remains elusive.

The cost structure is heavily weighted toward COGS, which is typical for a refiner, but the extreme swings in gross margin indicate that the company has limited ability to pass through input cost increases. SG&A has ranged from $24.4M to $78.3M, with the 2026Q1 spike suggesting possible one-time charges or inefficiencies, but it is not the primary driver of profitability. The lack of R&D spending is notable for a specialty chemicals company, implying that innovation is not a current priority, which may limit long-term differentiation. Management's expense discipline appears weak, as SG&A has not been consistently reduced even during periods of negative gross profit.

This quarter appears to be a clear inflection point, but the subsequent collapse to negative margins in 2025Q4 and 2026Q1 suggests that it was not a durable improvement. The $373.7M gross profit in 2025Q3 is nearly ten times the next best quarter, indicating that it may have been driven by favorable inventory valuations or a temporary spike in renewable credit prices. The lasting impact of this inflection is minimal, as the company has since returned to losses, and it may have misled investors into expecting a turnaround. The volatility around this period underscores the difficulty in forecasting Calumet's earnings and the need to normalize for non-recurring items.